title: Hepatosplenic gamma-delta T-cell lymphoma.
abstract: Hepatosplenic T-cell lymphoma (HSTL) is a rare and aggressive extranodal lymphoma derived mostly from cytotoxic γδ T-cells. The peak incidence is in adolescents and young adults, and is more common in males. Up to 20% of HSTL arise in the setting of chronic immune suppression, most commonly solid organ transplantation or prolonged antigenic stimulation. Patients present with systemic symptoms (fever), abdominal pain, weakness, and marked hepatosplenomegaly in the absence of lymphadenopathy. Patients usually manifest marked thrombocytopenia, often with anaemia and leucopenia, a leukemic phase, and bone marrow involvement in 80% of cases. Lactate dehydrogenase levels are usually markedly elevated. HSTL exhibits a marked chemoresistance to currently used regimens, a rapidly progressive behavior, and dismal prognosis. Patients with post-transplant HSTL exhibit an especially poor outcome. Standard treatment has yet to be established. Anthracycline-based chemotherapy is associated with a satisfactory response in two thirds of patients, but poor long-term results. Complete remission is extremely uncommon, and most patients die from lymphoma within two years of diagnosis. A prognostic correlation between outcome and degree of thrombocytopenia has been reported. Relapsing disease is usually chemorefractory and fast growing, and patients' performance status and clinical conditions are poor. These aspects, as well as the lack of drugs with proven activity against HSTL, render salvage treatment almost impossible. A few cases of HSTL successfully treated with autologous or allogeneic stem-cell transplantation have been reported. The use of 2'-deoxycoformycin and other targeted therapies, such as alemtuzumab, anti-γδ TCR monoclonal antibodies, and anti-CD44 therapy, have shown promising results in anecdotal reports.
authors: Unit of Lymphoid Malignancies, Department of Onco-Hematology, San Raffaele Scientific Institute, Milan, Italy. andres.ferreri@hsr.it
authors: Andrés J M
authors: AJ
authors: Ferreri
authors: Silvia
authors: S
authors: Govi
authors: Stefano A
authors: SA
authors: Pileri
mesh_terms: D000074323:Alemtuzumab; D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008113:Liver Neoplasms / Q000453:epidemiology / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D016399:Lymphoma, T-Cell / Q000453:epidemiology / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D015649:Pentostatin / Q000627:therapeutic use; D016692:Receptors, Antigen, T-Cell, gamma-delta / Q000276:immunology*; D013160:Splenic Neoplasms / Q000453:epidemiology / Q000276:immunology* / Q000473:pathology / Q000628:therapy*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D016692:Receptors, Antigen, T-Cell, gamma-delta; D015649:Pentostatin; D000074323:Alemtuzumab